Form 4: Spero Therapeutics Director Patrick V.J.J. Vink Acquires 20,000 Shares of Common Stock

Director Patrick V.J.J. Vink acquired 20,000 shares of Spero Therapeutics common stock on May 29, 2024, through restricted stock units.

Summary

• On May 29, 2024, Patrick V.J.J. Vink, a director of Spero Therapeutics, acquired 20,000 shares of common stock.
• The acquisition was in the form of restricted stock units (RSUs).
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs vest on May 29, 2025, contingent upon Vink's continued service with the company.
• Following the transaction, Vink directly owns 55,000 shares of Spero Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction of a director acquiring shares, which is neither overtly positive nor negative.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a director's acquisition of company stock, which is a common occurrence.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates